Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty
Information source: Centro Medico Campinas
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hemolysis
Intervention: Propofol (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Centro Medico Campinas Official(s) and/or principal investigator(s): Ricardo F Simoni, MD, Principal Investigator, Affiliation: Fundação Centro Médico de Campinas
Summary
The purpose of this study is to determine if propofol could protect erythrocytes by directly
scavenging free radicals from the blood current and increasing resistance of their cell
membranes in patients submitted to gastroplasty.
Clinical Details
Official title: Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Count erythrocytes
Secondary outcome: Bilirubins(direct and indirect)
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients between BMI 40-50 kg/m2
Exclusion Criteria:
- patients with BMI under 40 kg/m2 and over 50 kg/m2
- alcohol users
- illicit-drug users
- patients in regular use of anti-depressants, proton bomb inhibitors or calcium canal
blockers
- patients transfused either recently, during the intra-operative period or within 10
hours post-operative
- patients previously known to be hypersensitive to any drug that is used during the
study
- patients with any psychiatric disorder or dementia
Locations and Contacts
Fundação Centro Médico de Campinas, Campinas, São Paulo 13084-000, Brazil
Additional Information
Starting date: November 2008
Last updated: November 4, 2009
|